Effect of the Calcium Channel Blocker Nisoldipine on the Progression of Chronic Renal Failure in Man

Publisher Website
Google Scholar
Abstract
Patients with stable renal insufficiency were randomized into two groups: (1) patients given the channel blocker nisoldipine (n = 17) and (2) placebo-treated patients (n = 17) also taking their regular antihypertensive therapy which did not include calcium blockers. Patients were already on low protein diet with a protein intake of 0.80 ± 0.2 in the nisoldipine group versus 0.85 ± 0.25 g/kg body weight in the placebo-treated group. The monthly progression of their renal failure was assessed by the reciprocal of serum creatinine versus time in months. After a mean follow-up of 17.4 ± 8.2 (range 6–30) months, the nisoldipine-treated group had a significant decrease in their slope of progression, whereas the placebo-treated patients, after 16.94 ± 7.2 (range 6–30) months of follow-up, had no significant change in their slope. The protein intake during follow-up was similar, being 0.85 ± 0.2 g/kg actual body weight in the nisoldipine-treated group and 0.88 ± 0.26 g/kg in the placebo group. The changes in slope did not correlate with the changes in blood pressure.

This publication has 1 reference indexed in Scilit: